Astec LifeSciences Ltd Stock Price Today (NSE: ASTEC)
Fundamental Score
Astec LifeSciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Astec LifeSciences Ltd share price today is ₹540.60, down 7.01% on NSE/BSE as of 30 March 2026. Astec LifeSciences Ltd (ASTEC) is a Small-cap company in the Pesticides & Agrochemicals sector with a market capitalisation of ₹1.82K (Cr). The 52-week high for ASTEC share price is ₹998.40 and the 52-week low is ₹513.40. The company has a Return on Equity (ROE) of -45.29% and a debt-to-equity ratio of 0.89.
Astec LifeSciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Astec LifeSciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Astec LifeSciences Share Price: A ROCE-Focused Analysis
The Pesticides & Agrochemicals sector is currently facing a complex landscape. While demand remains robust due to the increasing need for crop protection, companies are grappling with fluctuating raw material prices and intensified competition, directly impacting profitability and return on capital efficiency. This analysis focuses on Astec LifeSciences share price (₹635.9500122070312) through the lens of Return on Capital Employed (ROCE). With a current ROCE of -12.86% and a missing Price-to-Earnings (PE) ratio, a deep dive is crucial to understand the underlying drivers affecting the company's financial performance.
A concerning aspect is the negative ROCE. This suggests that Astec LifeSciences Ltd. is currently not efficiently deploying its capital to generate profits. While factors like short-term market headwinds or recent investments could contribute, a sustained negative ROCE can erode shareholder value over time. This contrasts sharply with companies that maintain a healthy ROCE, signaling strong capital management and profitability.
Comparing Astec LifeSciences Ltd. to its peers offers valuable context. For example, consider
Phyto Chem India Limited. While a direct comparison of management quality requires deeper qualitative analysis, a consistently higher ROCE at Phyto Chem India Limited *may* indicate a more effective deployment of capital and resource allocation. Further investigation would be necessary to understand the specific strategies driving this difference.The negative ROCE also directly impacts the company's economic moat, or its competitive advantage. A company with a strong ROCE typically has a wider moat, benefiting from pricing power and the ability to reinvest profits for future growth. The current -12.86% ROCE, if persistent, *could* weaken Astec LifeSciences’ moat, making it more vulnerable to competition and economic downturns. A turnaround strategy focused on improving operational efficiency and cost management *may* be necessary to bolster profitability and strengthen its market position.
This analysis is part of a comprehensive 80-parameter fundamental audit conducted on Astec LifeSciences Ltd. and has been verified by Sweta Mishra. The observations presented are based on publicly available data and should not be interpreted as investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Astec LifeSciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ASTEC across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (36.64%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Balanced Promoter Holding (72.42%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-45.29%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-12.86%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Revenue Contraction (-25.20%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-6.11% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-1.47x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-381.94 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 4.01%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Astec LifeSciences Ltd Financial Statements
Comprehensive financial data for Astec LifeSciences Ltd including income statement, balance sheet and cash flow
About ASTEC (Astec LifeSciences Ltd)
Astec LifeSciences Ltd is a pivotal player in the agrochemical sector, specializing in the meticulous creation of essential ingredients that underpin modern agriculture. The compan...y's expertise lies in synthesizing active ingredients for crop protection products, primarily focusing on triazole fungicides. These compounds are instrumental in safeguarding a wide spectrum of crops from fungal diseases, contributing to improved yields and reduced post-harvest losses. Astec meticulously engineers its products to meet the stringent demands of the agricultural industry, ensuring both efficacy and environmental responsibility. Through constant innovation and a commitment to sustainable practices, Astec LifeSciences strengthens its position as a reliable supplier for global crop protection companies. Beyond fungicides, Astec LifeSciences also produces a range of specialized chemical intermediates vital to the pharmaceutical industry. These intermediates serve as key building blocks for complex drug molecules, showcasing the company's versatile chemistry capabilities. This dual focus on agrochemicals and pharmaceutical intermediates positions Astec as a significant contributor to both food security and human health. The company invests significantly in research and development, constantly seeking to refine its processes and develop novel compounds that address emerging challenges in both agricultural and pharmaceutical sectors. Astec understands the importance of quality and precision in its manufacturing processes, assuring that its outputs adhere to the highest industry standards. Operating within India, Astec LifeSciences leverages its local expertise and infrastructure to serve a global clientele. The company strategically cultivates its strong relationships with both domestic and international clients. Astec's commitment to reliable supply chains, combined with a deep understanding of the agrochemical and pharmaceutical markets, makes it a trusted partner for organizations seeking high-quality chemical solutions. With its blend of scientific expertise, manufacturing proficiency, and a focus on responsible business practices, Astec LifeSciences contributes significantly to advancing agricultural productivity and pharmaceutical innovation.
Company Details
Key Leadership
Corporate Events
ASTEC Share Price: Frequently Asked Questions
What is the current share price of Astec LifeSciences Ltd (ASTEC)?
As of 30 Mar 2026, 12:02 pm IST, Astec LifeSciences Ltd share price is ₹540.60. The ASTEC stock has a market capitalisation of ₹1.82K (Cr) on NSE/BSE.
Is ASTEC share price Overvalued or Undervalued?
ASTEC share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 29.36x. Based on this relative valuation, the Astec LifeSciences Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of ASTEC share price?
The 52-week high of ASTEC share price is ₹998.40 and the 52-week low is ₹513.40. These values are updated daily from NSE/BSE price data.
What factors affect the Astec LifeSciences Ltd share price?
Key factors influencing ASTEC share price include quarterly earnings growth (Sales Growth: -25.20%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Astec LifeSciences Ltd a good stock for long-term investment?
Astec LifeSciences Ltd shows a 5-year Profit Growth of N/A% and an ROE of -45.29%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.89 before investing in ASTEC shares.
How does Astec LifeSciences Ltd compare with its industry peers?
Astec LifeSciences Ltd competes with major peers in the Pesticides & Agrochemicals. Investors should compare ASTEC share price P/E of 0.00x and ROE of -45.29% against the industry averages to determine competitive standing.
What is the P/E ratio of ASTEC and what does it mean?
ASTEC share price has a P/E ratio of N/Ax compared to the industry average of 29.36x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is ASTEC performing according to Bull Run's analysis?
ASTEC has a Bull Run fundamental score of 17/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ASTEC belong to?
ASTEC operates in the Pesticides & Agrochemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Astec LifeSciences Ltd share price.
What is Return on Equity (ROE) and why is it important for ASTEC?
ASTEC has an ROE of -45.29%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Astec LifeSciences Ltd generates profits from shareholders capital.
How is ASTEC debt-to-equity ratio and what does it indicate?
ASTEC has a debt-to-equity ratio of 0.89, which indicates moderate leverage that should be monitored.
What is ASTEC dividend yield and is it a good dividend stock?
ASTEC offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Astec LifeSciences Ltd shares.
How has ASTEC share price grown over the past 5 years?
ASTEC has achieved 5-year growth rates of: Sales Growth -6.11%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in ASTEC and why does it matter?
Promoters hold 72.42% of ASTEC shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Astec LifeSciences Ltd.
What is ASTEC market capitalisation category?
ASTEC has a market capitalisation of ₹1818 crores, placing it in the Small-cap category.
How volatile is ASTEC stock?
ASTEC has a beta of N/A. A beta > 1 suggests the Astec LifeSciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ASTEC operating profit margin trend?
ASTEC has a 5-year average Operating Profit Margin (OPM) of 10.02%, indicating the company's operational efficiency.
How is ASTEC quarterly performance?
Recent quarterly performance shows Astec LifeSciences Ltd YoY Sales Growth of -25.20% and YoY Profit Growth of 36.64%.
What is the institutional holding pattern in ASTEC?
ASTEC has FII holding of 0.00% and DII holding of 4.01%. Significant institutional holding often suggests professional confidence in the Astec LifeSciences Ltd stock.